Market Closed -
Nasdaq
21:00:00 02/05/2024 BST
|
5-day change
|
1st Jan Change
|
1.41
USD
|
-7.24%
|
|
-22.10%
|
-25.40%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
275.4
|
684.6
|
383.1
|
81.58
|
115.9
|
-
|
-
|
Enterprise Value (EV)
1 |
275.4
|
684.6
|
383.1
|
81.58
|
115.9
|
115.9
|
115.9
|
P/E ratio
|
-2.8
x
|
-8.75
x
|
-5.26
x
|
-0.57
x
|
-0.77
x
|
-0.75
x
|
-0.72
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
15.4
x
|
70.4
x
|
15.3
x
|
-
|
-
|
32.4
x
|
18.5
x
|
EV / Revenue
|
15.4
x
|
70.4
x
|
15.3
x
|
-
|
-
|
32.4
x
|
18.5
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-10.8
x
|
-
|
-0.83
x
|
-1.41
x
|
-1.31
x
|
-1.22
x
|
FCF Yield
|
-
|
-9.29%
|
-
|
-120%
|
-70.8%
|
-76.6%
|
-82%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
19,601
|
39,143
|
42,851
|
43,165
|
82,170
|
-
|
-
|
Reference price
2 |
14.05
|
17.49
|
8.940
|
1.890
|
1.410
|
1.410
|
1.410
|
Announcement Date
|
11/03/21
|
15/03/22
|
15/03/23
|
19/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
17.9
|
9.73
|
24.99
|
-
|
-
|
3.571
|
6.25
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-39.19
|
-61.43
|
-72.55
|
-152
|
-127.8
|
-128.4
|
-126
|
Operating Margin
|
-218.91%
|
-631.38%
|
-290.32%
|
-
|
-
|
-3,595.45%
|
-2,015.95%
|
Earnings before Tax (EBT)
1 |
-39.49
|
-62.12
|
-69.79
|
-142.7
|
-121.7
|
-125.3
|
-124.4
|
Net income
1 |
-36.68
|
-62
|
-69.79
|
-142.7
|
-121.7
|
-125.3
|
-124.4
|
Net margin
|
-204.87%
|
-637.19%
|
-279.27%
|
-
|
-
|
-3,508.89%
|
-1,991.03%
|
EPS
2 |
-5.010
|
-2.000
|
-1.700
|
-3.310
|
-1.840
|
-1.873
|
-1.968
|
Free Cash Flow
1 |
-
|
-63.59
|
-
|
-98.18
|
-82
|
-88.7
|
-95
|
FCF margin
|
-
|
-653.51%
|
-
|
-
|
-
|
-2,483.6%
|
-1,520%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/03/21
|
15/03/22
|
15/03/23
|
19/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
3.429
|
5.468
|
24.99
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-13.71
|
-15.54
|
4.706
|
-22.71
|
-22.98
|
-31.56
|
-33.32
|
-34.89
|
-52.26
|
-31.57
|
-30.22
|
-30.79
|
-31.49
|
-32.25
|
Operating Margin
|
-399.83%
|
-284.24%
|
18.83%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-14
|
-15.82
|
4.618
|
-22.54
|
-22
|
-29.88
|
-30.88
|
-32.4
|
-49.88
|
-29.49
|
-28.79
|
-28.93
|
-29.76
|
-30.66
|
Net income
1 |
-14.01
|
-15.81
|
4.618
|
-22.54
|
-22
|
-29.88
|
-30.88
|
-32.4
|
-49.88
|
-29.49
|
-28.79
|
-28.93
|
-29.76
|
-30.66
|
Net margin
|
-408.66%
|
-289.19%
|
18.48%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.4400
|
-0.4700
|
0.1000
|
-0.5600
|
-0.5300
|
-0.7200
|
-0.7200
|
-0.7500
|
-1.160
|
-0.6900
|
-0.3940
|
-0.3560
|
-0.3660
|
-0.3800
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
10/11/21
|
15/03/22
|
12/05/22
|
10/08/22
|
08/11/22
|
15/03/23
|
09/05/23
|
09/08/23
|
08/11/23
|
19/03/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-63.6
|
-
|
-98.2
|
-82
|
-88.7
|
-95
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-23.4%
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-20.8%
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
334.8
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
13
|
-
|
4.46
|
3.97
|
5.98
|
4.83
|
Capex / Sales
|
-
|
134.08%
|
-
|
-
|
-
|
167.48%
|
77.33%
|
Announcement Date
|
11/03/21
|
15/03/22
|
15/03/23
|
19/03/24
|
-
|
-
|
-
|
Last Close Price
1.41
USD Average target price
9.6
USD Spread / Average Target +580.85% Consensus |
1st Jan change
|
Capi.
|
---|
| -25.40% | 125M | | +26.28% | 42.68B | | -3.99% | 42.4B | | +45.32% | 40.04B | | -6.20% | 28.31B | | +6.36% | 24.94B | | -21.47% | 18.96B | | +27.58% | 12.3B | | -2.75% | 11.95B | | -2.02% | 11.55B |
Other Biotechnology & Medical Research
|